S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: Asian shares shrug off Wall St blues as China leaves lending rate unchanged
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

$12.05
+0.40 (+3.43%)
(As of 04/19/2024 08:51 PM ET)
Today's Range
$11.50
$12.20
50-Day Range
$4.12
$14.17
52-Week Range
$3.35
$16.40
Volume
1.01 million shs
Average Volume
976,811 shs
Market Capitalization
$557.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.63

Stoke Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
62.9% Upside
$19.63 Price Target
Short Interest
Bearish
15.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.59
Upright™ Environmental Score
News Sentiment
0.24mentions of Stoke Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$41.98 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.28) to ($2.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.13 out of 5 stars

Medical Sector

150th out of 908 stocks

Pharmaceutical Preparations Industry

52nd out of 414 stocks

STOK stock logo

About Stoke Therapeutics Stock (NASDAQ:STOK)

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

STOK Stock Price History

STOK Stock News Headlines

Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Global crypto currency reset (41 major banks signed up)
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Stoke Therapeutics, Inc. (NASDAQ:STOK) Short Interest Update
Assessing Stoke Therapeutics: Insights From 6 Financial Analysts
See More Headlines
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/25/2024
Today
4/21/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.63
High Stock Price Target
$35.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+62.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-104,700,000.00
Pretax Margin
-1,192.47%

Debt

Sales & Book Value

Annual Sales
$8.78 million
Book Value
$3.57 per share

Miscellaneous

Free Float
40,609,000
Market Cap
$557.92 million
Optionable
Optionable
Beta
0.77
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Edward M. Kaye M.D.Dr. Edward M. Kaye M.D. (Age 75)
    Ph.D., CEO & Director
    Comp: $931.21k
  • Dr. Adrian R. Krainer Ph.D. (Age 65)
    Co-Founder & Independent Director
    Comp: $44k
  • Mr. Stephen J. Tulipano CPA (Age 65)
    MBA, Chief Financial Officer
    Comp: $619.09k
  • Dr. Barry S. Ticho FACC (Age 63)
    M.D., Ph.D., Chief Medical Officer
    Comp: $688.83k
  • Ms. Isabel Aznarez Ph.D. (Age 51)
    Co-Founder & Group VP of Discovery Research
  • Dr. Huw M. Nash Ph.D. (Age 57)
    COO & Chief Business Officer
    Comp: $429.67k
  • Mr. Eric Rojas
    Head of Investor Relations
  • Mr. Jonathan Allan J.D. (Age 34)
    Corporate Secretary & General Counsel
  • Ms. Dawn Kalmar (Age 46)
    Chief Communications Officer
  • Ms. Joan Wood
    Chief Human Resources Officer

STOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Stoke Therapeutics stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STOK shares.
View STOK analyst ratings
or view top-rated stocks.

What is Stoke Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued 12 month price targets for Stoke Therapeutics' stock. Their STOK share price targets range from $12.00 to $35.00. On average, they expect the company's stock price to reach $19.63 in the next twelve months. This suggests a possible upside of 62.9% from the stock's current price.
View analysts price targets for STOK
or view top-rated stocks among Wall Street analysts.

How have STOK shares performed in 2024?

Stoke Therapeutics' stock was trading at $5.26 at the beginning of the year. Since then, STOK shares have increased by 129.1% and is now trading at $12.05.
View the best growth stocks for 2024 here
.

Are investors shorting Stoke Therapeutics?

Stoke Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,950,000 shares, an increase of 39.4% from the March 15th total of 3,550,000 shares. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is currently 4.9 days. Currently, 15.0% of the company's shares are short sold.
View Stoke Therapeutics' Short Interest
.

When is Stoke Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our STOK earnings forecast
.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics, Inc. (NASDAQ:STOK) posted its quarterly earnings results on Monday, March, 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.62) by $0.02. The company earned $2.80 million during the quarter, compared to the consensus estimate of $3.70 million.

What ETFs hold Stoke Therapeutics' stock?

ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and WisdomTree BioRevolution Fund (WDNA).Global X Genomics & Biotechnology ETF (GNOM).

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

When did Stoke Therapeutics IPO?

Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

How do I buy shares of Stoke Therapeutics?

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:STOK) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners